Structure Therapeutics reports compelling data on obesity candidate GSBR-1290

4 June 2024

Shares of US biotech Structure Therapeutics (Nasdaq: GPCR) shot up as much as 71% yesterday and gained a further 4.6% to $55.17 in pre-market activity on the back of encouraging research results on its oral GLP-1 weight management candidate.

San Francisco-based Structure announced positive 12-week top-line obesity data from its Phase IIa study of GSBR-1290, along with positive top-line results from its capsule to tablet PK study. Both studies achieved their primary and secondary objectives.

Leerink Partners analyst David Risinger said "GSBR-1290 delivers compelling obesity efficacy and looks comparable to Eli Lilly's experimental weight-loss pill orforglipron, based on the results after three months of treatment."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK